Liaoning Medical College, Jinzhou, 121001, China.
Mol Biol Rep. 2013 Feb;40(2):1835-41. doi: 10.1007/s11033-012-2238-z. Epub 2012 Oct 21.
The association between COMT Val158Met polymorphism and prostate cancer has been evaluated. However, the results of these studies on the association remain conflicting. To derive a more precise estimation of the relationship, a meta-analysis was performed. A comprehensive search was conducted to identify the eligible studies of COMT Val158Met polymorphism and prostate cancer risk. Summary odds ratios (OR) and 95 % confidence interval (CI) for COMT Val158Met polymorphism and prostate cancer were calculated. Statistical analysis was performed with the software program Review Manage (Version 5.0) and Stata (Version 12.0). Six case-control studies, totally 4,118 persons including 2,143 cases and 1,975 controls, met the included criteria and thus were selected. Our analysis suggested that Val158Met polymorphism was associated with prostate cancer risk in overall population. Collectively, the results of the present study suggest that significant associations of COMT Val158Met polymorphisms with prostate cancer were observed (for additive model: OR = 1.068, 95 % CI = 1.002-1.138, P (heterogeneity) = 0.363, P = 0.043; for dominant model: OR = 1.266, 95 % CI = 1.057-1.517, P (heterogeneity) = 0.000, P = 0.011; for recessive model: OR = 1.050, 95 % CI = 0.961-1.146, P (heterogeneity) = 0.558, P = 0.279; and Val allele versus Met allele OR = 0.932, 95 % CI = 0.894-0.971, P (heterogeneity) = 0.272, P = 0.001). In the subgroup analysis, we detected no significant association between the COMT 158 Val/Met genotype and prostate cancer risk in Caucasian and Asian populations, while the contrary result for additive model (OR = 2.43, 95 % CI = 1.08-5.43, P (heterogeneity) = 0.04, P = 0.03) in Asian populations. The result of this meta-analysis suggests that COMT l58Val/Met polymorphism might be contributed to the overall prostate cancer risk.
COMT Val158Met 多态性与前列腺癌的相关性已被评估。然而，这些研究的结果仍然存在争议。为了更准确地评估这种关系，进行了荟萃分析。进行了全面的搜索，以确定 COMT Val158Met 多态性与前列腺癌风险的合格研究。计算了 COMT Val158Met 多态性与前列腺癌的汇总优势比（OR）和 95%置信区间（CI）。使用软件程序 Review Manage（版本 5.0）和 Stata（版本 12.0）进行统计分析。符合纳入标准的共有 6 项病例对照研究，共 4118 人，包括 2143 例病例和 1975 例对照。我们的分析表明，Val158Met 多态性与总体人群中的前列腺癌风险相关。总的来说，本研究的结果表明，COMT Val158Met 多态性与前列腺癌显著相关（对于加性模型：OR=1.068，95%CI=1.002-1.138，P（异质性）=0.363，P=0.043；对于显性模型：OR=1.266，95%CI=1.057-1.517，P（异质性）=0.000，P=0.011；对于隐性模型：OR=1.050，95%CI=0.961-1.146，P（异质性）=0.558，P=0.279；Val 等位基因与 Met 等位基因的 OR=0.932，95%CI=0.894-0.971，P（异质性）=0.272，P=0.001）。在亚组分析中，我们未检测到 COMT 158 Val/Met 基因型与白种人和亚洲人群中前列腺癌风险之间的显著关联，而在亚洲人群中，加性模型的结果相反（OR=2.43，95%CI=1.08-5.43，P（异质性）=0.04，P=0.03）。这项荟萃分析的结果表明，COMT l58Val/Met 多态性可能与总体前列腺癌风险有关。
